Legis Daily

A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics.

USA115th CongressS-1113| Senate 
| Updated: 5/11/2017
Dianne Feinstein

Dianne Feinstein

Democratic Senator

California

Cosponsors (16)
Jeanne Shaheen (Democratic)Mazie K. Hirono (Democratic)Margaret Wood Hassan (Democratic)Tom Udall (Democratic)Patrick J. Leahy (Democratic)Kirsten E. Gillibrand (Democratic)Christopher A. Coons (Democratic)Kamala D. Harris (Democratic)Angus S. King (Independent)Amy Klobuchar (Democratic)Sheldon Whitehouse (Democratic)Michael F. Bennet (Democratic)Benjamin L. Cardin (Democratic)Susan M. Collins (Republican)Richard Blumenthal (Democratic)Shelley Moore Capito (Republican)

Health, Education, Labor, and Pensions Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Personal Care Products Safety Act This bill amends the Federal Food, Drug, and Cosmetic Act to require cosmetics companies to register their facilities with the Food and Drug Administration (FDA) and to submit to the FDA cosmetic ingredient statements that include the amounts of a cosmetic's ingredients. Companies must pay a facility registration fee based on their annual gross sales of cosmetics. The collected fees can only be used for cosmetic safety activities. If the FDA determines that a cosmetic has a reasonable probability of causing serious adverse health consequences, it may prohibit the cosmetic's distribution by suspending the cosmetic ingredient statement. If other cosmetics from the same facility may be affected, the FDA may prohibit distribution from the facility by suspending the facility's registration. The FDA must review the safety of at least five cosmetic ingredients each year, and it may establish conditions for safe use of an ingredient, including a limit on the amount of the ingredient or a requirement for a warning label. A cosmetic cannot be sold if it contains an ingredient that is not safe, not safe under the recommended conditions of use, or not safe in the amount present in the cosmetic. Cosmetics companies are required to report to the FDA any serious adverse health event associated with their cosmetics. The FDA must: develop and implement cosmetic manufacturing standards that are consistent with existing national and international standards, be allowed to inspect a company's cosmetic safety records, recall a cosmetic that is likely to cause serious adverse health consequences, and encourage cosmetic safety testing practices that minimize the use of animals.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
May 11, 2017
Introduced in Senate
May 11, 2017
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2918-2919)
  • May 11, 2017
    Introduced in Senate


  • May 11, 2017
    Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2918-2919)

Health

Animal protection and human-animal relationshipsBusiness recordsCoalConsumer affairsDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationEmployee hiringFederal preemptionFood and Drug Administration (FDA)Government information and archivesInflation and pricesLicensing and registrationsManufacturingProduct safety and qualitySmall businessState and local government operationsUser charges and fees

A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics.

USA115th CongressS-1113| Senate 
| Updated: 5/11/2017
Personal Care Products Safety Act This bill amends the Federal Food, Drug, and Cosmetic Act to require cosmetics companies to register their facilities with the Food and Drug Administration (FDA) and to submit to the FDA cosmetic ingredient statements that include the amounts of a cosmetic's ingredients. Companies must pay a facility registration fee based on their annual gross sales of cosmetics. The collected fees can only be used for cosmetic safety activities. If the FDA determines that a cosmetic has a reasonable probability of causing serious adverse health consequences, it may prohibit the cosmetic's distribution by suspending the cosmetic ingredient statement. If other cosmetics from the same facility may be affected, the FDA may prohibit distribution from the facility by suspending the facility's registration. The FDA must review the safety of at least five cosmetic ingredients each year, and it may establish conditions for safe use of an ingredient, including a limit on the amount of the ingredient or a requirement for a warning label. A cosmetic cannot be sold if it contains an ingredient that is not safe, not safe under the recommended conditions of use, or not safe in the amount present in the cosmetic. Cosmetics companies are required to report to the FDA any serious adverse health event associated with their cosmetics. The FDA must: develop and implement cosmetic manufacturing standards that are consistent with existing national and international standards, be allowed to inspect a company's cosmetic safety records, recall a cosmetic that is likely to cause serious adverse health consequences, and encourage cosmetic safety testing practices that minimize the use of animals.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
May 11, 2017
Introduced in Senate
May 11, 2017
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2918-2919)
  • May 11, 2017
    Introduced in Senate


  • May 11, 2017
    Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2918-2919)
Dianne Feinstein

Dianne Feinstein

Democratic Senator

California

Cosponsors (16)
Jeanne Shaheen (Democratic)Mazie K. Hirono (Democratic)Margaret Wood Hassan (Democratic)Tom Udall (Democratic)Patrick J. Leahy (Democratic)Kirsten E. Gillibrand (Democratic)Christopher A. Coons (Democratic)Kamala D. Harris (Democratic)Angus S. King (Independent)Amy Klobuchar (Democratic)Sheldon Whitehouse (Democratic)Michael F. Bennet (Democratic)Benjamin L. Cardin (Democratic)Susan M. Collins (Republican)Richard Blumenthal (Democratic)Shelley Moore Capito (Republican)

Health, Education, Labor, and Pensions Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Animal protection and human-animal relationshipsBusiness recordsCoalConsumer affairsDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationEmployee hiringFederal preemptionFood and Drug Administration (FDA)Government information and archivesInflation and pricesLicensing and registrationsManufacturingProduct safety and qualitySmall businessState and local government operationsUser charges and fees